Factor xa inhibition: Correlation between the plasma levels of anti-xa activity and occurrence of thrombosis and haemorrhage

Pathophysiology of Haemostasis and Thrombosis

Volumn 23, Issue , 1993, Pages 89-98

  Leizorovicz, Alain ^a   Bara, L ^b   Samama, M M ^b   Haugh, M C ^a  

^a Laboratoire Glaxo Wellcome   (France)

^b Laboratoirc Central d’Hématologie ^*  (France)

Author keywords

Anti Xa activity; General surgery; Haemorrhage; Heparin; Low molecular weight; Thromboprophylaxis; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

BLEEDING; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURGICAL PATIENT; THROMBOSIS; THROMBOSIS PREVENTION;

BODY WEIGHT; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; FACTOR XA; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; INCIDENCE; MALE; MIDDLE AGE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; THROMBOPHLEBITIS;

EID: 0027399508     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000216915     Document Type: Article

References (21)

1. Collins R, Scrimgeour A, Yusuf S, Peto R: Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988;318:1 162-1173.
2. Bara L, Billaud E, Kher A, Samama M: Increased anti-Xabioavailability for a low molecular heparin (PK 10169) compared with unfractionated heparin. Semin Thromb Hemost 1985;11:316-317.
3. Frydman AM, Bara L, Roux Y, Woler M, Chauliac F, Samama M: The antithrombotic activity of Enoxaparin, a low molecular weight heparin, in humans given subcutaneous doses of 60 to 80 mg. J Clin Pharmacol 1988;26:609-618.
4. Holmer E, Mattsson C, Nilsson S: Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin in rabbits. Thromb Res 1982;25:475-485.
5. Buchanan MR, Boneu B, Ofosu F, Hirsh J: The relative importance of thrombin inhibition or factor Xa inhibition to the anti thrombotic effect of heparin. Blood 1985;65:198-201.
6. Bara L, Trillou M, Mardiguian J, Samama M: Comparison of antithrombotic activity of two heparin fragments PK 10169 (MW 5,000) and EMT 680 (MW 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: Relative importance of systemic anti Xa and anti IIa activities. Nouv Rev Fr Hematol 1986;28:355-358.
7. Bara L, Samama M: Antithrombotic activity of various heparin oligosaccharides in relation with their in vivo and ex vivo anti-IIa activity in the rabbit. Thromb Haemost 1989;62:940-944.
8. Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick PG: Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery: A randomized, double-blind study versus unfractionated heparin. Thromb Haemost 1986;56:243-246.
9. Levine MN, Planes A, Hirsh J, Godgla M, Vochelle N, Gent M: The relationship between anti factor Xa level and clinical outcome in patients receiving Enoxaparin, a low molecular weight heparin, to prevent deep vein thrombosis after hip replacement. Thromb Haemost 1989;62:940-944.
10. Leizorovicz A, Picolet H, Peyrieux JC, Boissel JP and the HBPM Research Group: Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 1991;78:412-416.
11. Post-surgery Logiparin Study Group, Bara L, Leizorovicz A, Picolet H, Samama M: Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in postsurgical patients treated with either Logiparin(r) (LMWH) or unfractionated heparin. Thromb Res 1992;65:641-650.
12. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Bossel JP: Lowmolecular weight heparin in the prevention of peri-operative thrombosis. Br Med J 1992;305:913-920.
13. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward J, Mayo W, Rosenbloom D, Brant R: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982.
14. Fricker JP, Vergnes Y, Schach R: Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin(r)) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561-567.
15. Bara L, Combe-Tamzali S, Conard J, Horellou MH, Samama M: Modifications biologiques induites par trois héparines de bas poids moléculaire PK 10169, Kabi 2165 et Cy 216, comparées à I’héparire non fractionnée, injectées par voie souscutanée chez le volontaire sain en Chirurgie générale et chez le sujet âgé en médecine. J Mal Vasc 1987;12:78-84.
16. Vitoux JF, Aiach M, Roncato M; Fiessinger JN: Should thromboprophylactic dosage of low molecular weight be adapted to patient’s weight? Thromb Haemost 1988;59:120.
17. Leyvraz P, Bachmann F, Hoek J, Büller HR, Postel M, Samama M, Vandenbroek MD: Prevention of deep vein thrombosis after hip replacement: Randomized comparison between unfractionated heparin and low molecular weight heparin. Br Med J 1991;303:543-548.
18. The Danish Enoxaparin Study Group: Low-molecular weight heparin (Enoxaparin) vs dextran 70. Arch Intern Med 1991;151:1612-1624.
19. Beguin S, Lindhout T, Hemker HC: The mode of action of heparin in plasma. Thromb Haemost 1988;60:457-462.
20. Ofosu FA: Mechanisms for the anticoagulant effect of heparin and related polysaccharides. Nouv Rev Fr Hematol 1988;30:155-160.
21. Hartl P, Brücke P, Dienstl E, Vinazzer H: Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and fragmin. Thromb Res 1990;57:577-584.